ABVX:NASDAQ
Abivax SA
$76.63
arrow_downward
-40.91%(-53.06) 1D
Jun 2, 10:55:41 AM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
$77.52
High
$83.34
Low
$74.00
Mkt. cap
5.32B
Avg. vol.
1.21M
Volume
8.61M
52-wk high
$148.83
52-wk low
$5.69
Shares outstanding
79.77M
No. of employees
80
Open
$77.52
High
$83.34
Low
$74.00
Mkt. cap
5.32B
Avg. vol.
1.21M
Volume
8.61M
52-wk high
$148.83
52-wk low
$5.69
Shares outstanding
79.77M
No. of employees
80
News stories
From sources across the web
Axios
·
27 minutes ago
Abivax share plunge may change deal outlook
Quartz
·
49 minutes ago
Abivax stock plunges on cancer signal in ulcerative colitis trial
Investing.com Australia
·
52 minutes ago
Truist cuts Abivax stock price target on malignancy concerns By Investing.com
Investor's Business Daily
·
1 hour ago
Why This Biotech Plummeted Despite Its 'Best-Case' Study
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees80
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Websiteabivax.com
AI content may include mistakes. Learn more